alendronate has been researched along with Neointima in 1 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Neointima: The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Généreux, P | 1 |
| Chernin, G | 1 |
| Assali, AR | 1 |
| Peruga, JZ | 1 |
| Robinson, SD | 1 |
| Schampaert, E | 1 |
| Bagur, R | 1 |
| Mansour, S | 1 |
| Rodés-Cabau, J | 1 |
| McEntegart, M | 1 |
| Gerber, R | 1 |
| L'Allier, P | 1 |
| de Silva, R | 1 |
| Daneault, B | 1 |
| Aggarwal, SK | 1 |
| Džavík, V | 1 |
| Ozan, MO | 1 |
| Ben-Yehuda, O | 1 |
| Maehara, A | 1 |
| Stone, GW | 1 |
| Jonas, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention[NCT02645799] | Phase 2 | 270 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for alendronate and Neointima
| Article | Year |
|---|---|
Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial.
Topics: Alendronate; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; | 2022 |